Premium
89bio Inc (ETNB)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast ... 89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.64 | 41.3793103448 | 6.38 | 11.77 | 6.38 | 7420859 | 8.72074008 | CS |
| 4 | 1.14 | 14.4670050761 | 7.88 | 11.77 | 5.9857 | 2552458 | 8.1955735 | CS |
| 12 | -0.23 | -2.48648648649 | 9.25 | 11.77 | 5.9857 | 1559388 | 8.22922008 | CS |
| 26 | -0.22 | -2.38095238095 | 9.24 | 11.77 | 5.9857 | 1004164 | 8.22672628 | CS |
| 52 | -1.16 | -11.394891945 | 10.18 | 16.63 | 5.9857 | 1054486 | 9.09763823 | CS |
| 156 | 2.84 | 45.9546925566 | 6.18 | 22.93 | 2 | 1117851 | 10.94768693 | CS |
| 260 | -18.7 | -67.4603174603 | 27.72 | 47.2532 | 2 | 710035 | 11.71406739 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
